Bozinoff N, Kleinman RA, Sloan ME, Kennedy MC, Nolan S, Selby P, Kalocsai C, Wood E Rethinking substance use as social history: charting a way forward J Gen Intern Med PubMed

Wood E, Pan J, Cui Z, Bach P, Dennis B, Nolan S, Socías ME Does this patient have alcohol use disorder?: The rational clinical examination systematic review JAMA PubMed

Wood E, Bach P Fatal drug overdose risks of health care workers in the United States Ann Intern Med PubMed

Crepeault H, Ti L, Jutras-Aswad D, Wood E, Le Foll B, Lim R, Bach P, Brar R, Socías ME Correlates of nonfatal overdose among treatment-seeking individuals with non-heroin opioid use disorder: findings from a pragmatic, pan-Canadian, randomized control trial J Subst Use Addict Treat PubMed

Mocanu V, Bozinoff N, Wood E, Jutras-Aswad D, Le Foll B, Lim R, Choi JC, Mok WY, Socías ME; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: secondary analysis of a pragmatic randomized trial Drug Alcohol Depend PubMed

Tobias S, Grant CJ, Laing R, Lysyshyn M, Buxton JA, Tupper KW, Wood E, Ti L What impact did the COVID-19 pandemic have on the variability of fentanyl concentrations in the Vancouver, Canada illicit drug supply? An interrupted time-series analysis BMJ Public Health Link

Socías ME, Wood E, Le Foll B, Lim R, Choi JC, Mok WY, Bruneau J, Rehm J, Wild TC, Bozinoff N, Hassan A, Jutras-Aswad D, OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial Addiction PubMed

Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, Rehm J, Wild TC, Wood E, Brissette S, Gagnon L, Fikowski J, Ledjiar O, Masse B, Socías ME, OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse Flexible buprenorphine/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: an open-label, pragmatic, noninferiority randomized controlled trial Am J Psychiatry PubMed

Nolan S, Kelian S, Kerr T, Young S, Malmgren I, Ghafari C, Harrison S, Wood E, Lysyshyn M, Holliday E Harm reduction in the hospital: an overdose prevention site (OPS) at a Canadian hospital Drug Alcohol Depend PubMed

Nosyk B, Min JE, Pearce LA, Zhou H, Homayra F, Wang L, Piske M, McCarty D, Gardner G, O’Briain W, Wood E, Daly P, Walsh T, Henry B Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada Drug and Alcohol Dependence PubMed